In: Business and Management

Submitted By dadzie
Words 2457
Pages 10

MOP Micro Finance Ltd stands for (MICHAEL OBAKUMAH PERCY) an acronym formed on school bucket in the 80s. The company started on the dining table around September 2009 and it has grown beyond the acronym.
The business started to grow from 2010 and MOP Finance Ltd was formed and registered at the Registrar Generals' Department as a Micro Finance company on the 23rd March 2010 which happens to be my birth date.
The name of the company later changed to MOP Micro Finance Ltd to conform to regulatory requirements of Bank of Ghana. The company grew from a mere asset base of GHc5,000 to about GHc1,000,000 in just three years.
Bringing tailor made micro banking and financial services to the reach of women, underprivileged and the poor in every community with a population size of 7000 in Ghana by 2030.
We intend to build a culture of savings, empowering women through financial freedom and wealth acquisition, micro lending to the poor and underprivileged and to also demystify banking services. MOP Microfinance Limited is one of the leading and preferred microfinance companies in Ghana.
We offer comprehensive financial solutions at the micro level to our valued clients in a professional, caring, responsive and profitable way. Our products are preferred because we listen to your needs and work with you to ensure a complete solution to your financial problems in a timely manner. | | The following are product that are offered by MOP Microfinance Company. * Personal Loans * Workers Loans * Business Loans * SME Loans |

During my internship programme with MOP Microfinance I realize I have a good communication skills. I was the secretary and also the front desk personnel. I sometimes welcome people into the office and anyone who comes for enquires concerning our services were directed to…...

Similar Documents

The Recalcitrant Director at Byte Products, Inc.: Corporate Legality Versus Corporate Responsibility

...Alzheimer’s disease (Aricept), neovascular (wet) age-related macular degeneration (Macugen), Parkinson’s disease (Mirapex), hypertension (Exforge and Olmetec), multiple sclerosis (Rebif) and chronic obstructive pulmonary disease (Spiriva) 2007 2006 08/07 07/06 129 2,251 1,541 1,789 1,569 1,374 (92) 26 (2) 30 (a) Represents direct sales under license agreement with Eisai Co., Ltd. Certain amounts and percentages may reflect rounding adjustments. Source: Pfizer’s 2008 Form 10k. EXHIBIT 2 The Proposed Wyeth Merger Benefits to Pfizer Wyeth diversifies offering and expands presence in EMS Pfizer inc Pharmaceuticals Primary care Specialty Care Oncology Established Products Research Pflizer Global R&D Market presence Significant in Emerging Markets Pfizer inc + Wyeth Biopharmaceuticals Primary care Specialty Care Vaccines Biologics Oncology Established Products Diversified businesses Animal Health Capsugel Consumer Health Nutritional Health Research Pharma Therapeutics Research Group Bio Therapeutics Research Group Market presence Enhanced in Emerging Markets Source: EXHIBIT 3 Total Revenues by Business Segment 2008 Pharmaceuticals Animal Health Corporate Other TOTAL REVENUES 2007 2006 91.5% 5.8% 2.7% 100.0% 91.8% 5.4% 2.8% 100.0% 93.2% 4.8% 2.0% 100.0% Source: Pfizer Annual Report (2008). Operating a global business is......

Words: 329712 - Pages: 1319